News & Views
News,
Telix currently generates most of its revenue from U.S. sales of Illuccix®. Because of the “just-in-time” nature of radiopharmaceutical products, such products are generally manufactured in close proximity to the…
Read more
Telix today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform,…
Read more
Telix today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic…
Read more
Telix today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68…
Read more
Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco,…
Read more
Telix today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4…
Read more
Telix today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic…
Read more
Telix today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology…
Read more
Telix and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)…
Read more
Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®, 89Zr- girentuximab) kidney cancer…
Read more